Toxoplasmosis Frequency Rate in Rheumatoid Arthritis Pa-tients in Northeastern Iran
Background: Toxoplasmosis is a zoonotic disease caused by the parasite Toxoplasma gondii, a cosmopolitan intracellular parasite. It can be a risk factor for autoimmune diseases, including rheumatoid arthritis (RA). This study was designed to investigate the possible association between serological history of T. gondii infection and defined clinical manifestation of RA in Northeast of Iran.
Methods: Overall, serum samples were collected from 50 RA patients and 40 healthy controls, from Qaem Hospital in Mashhad City, northeastern Iran in 2018. Seroprevalence of T. gondii infection was determined by ELISA.
Results: The prevalence of anti -T. gondii IgG in RA patients 48% (24.50) was significantly higher than the control group 10% (4.40) (P <0.001). Erythrocyte sedimentation rate (ESR), anti-cyclic citrullinated peptide (anti-CCP) and (rheumatoid factor) RF levels between the RA and control groups (P <0.01). Control group were matched with patients for age, gender and living area.
Conclusion: Given that a high correlation has been demonstrated between positivity rate of anti-T. gondii IgG and RA in Northeastern Iran, further studies will be necessary to clarify the pathogenesis of T. gondii among these patients.
2. Tian AL, Gu YL, Zhou N, et al. Seroprevalence of Toxoplasma gondii infection in arthritis patients in eastern China. Infect Dis Poverty. 2017; 6(1):153.
3. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Eng J Med. 2011; 365(23):2205-19.
4. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology(Oxford). 2013; 52(1):53-61.
5. Germano V, Cattaruzza MS, Osborn J, et al. Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists. J Transl Med. 2014; 12(1):77.
6. Shapira Y, Agmon-Levin N, Selmi C, et al. Prevalence of anti-Toxoplasma antibodies in patients with autoimmune diseases. J Autoimmun. 2012; 39(1-2):112-6.
7. Donahoe SL, Phalen DN, McAllan BM, et al. Differential gamma interferon-and tumor necrosis factor alpha-driven cytokine response distinguishes acute infection of a metatherian host with Toxoplasma gondii and Neospora caninum. Infect Immun. 2017; 85(6):e00173-17.
8. Derouich‐Guergour D, Aldebert D, Vigan I, et al. Toxoplasma gondii infection can regulate the expression of tumour necorsis factor‐α receptors on human cell in vitro. Parasite Immunol. 2002; 24(5):271-9.
9. Moudgil KD, Choubey D. Cytokines in autoimmunity: role in induction, regulation, and treatment. Journal Interferon Cytokine Res. 2011; 31(10):695-703.
10. Schulze-Koops H, Kalden JR. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2001; 15(5):677-91.
11. Mordue DG, Monroy F, La Regina M, et al. Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines. J Immunol. 2001; 167(8):4574-84.
12. Hosseininejad Z, Sharif M, Sarvi S, et al. Toxoplasmosis seroprevalence in rheumatoid arthritis patients: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2018; 12(6):e0006545.
13. Bas S, Genevay S, Meyer O, et al. Anti‐cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology. 2003; 42(5):677-80.
14. Wu JF, Yang YH, Wang LC, et al. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in juvenile rheumatoid arthritis. Clin Exp Rheumatol. 2007; 25(5):782.
15. Fischer S, Agmon-Levin N, Shapira Y, et al. Toxoplasma gondii: bystander or cofactor in rheumatoid arthritis. Immunol Res. 2013; 56(2-3):287-92.
16. Bouratbine A, Siala E, Chahed M, et al. Sero-epidemiologic profile of toxoplasmosis in northern Tunisia. Parasite (Paris, France). 2001; 8(1):61-6.
17. El-Sayed NM, Kishik SM, Fawzy RM. The current status of Toxoplasma gondii infection among Egyptian rheumatoid arthritis patients. Asian Pac J Trop Dis. 2016; 6(10):797-801.
18. Masoori L, Rezaei N, Molazadeh M, Alizadeh S, Hassanpour H. Development of rheumatoid arthritis by toxoplasmosis in Iranian patients. J Kerman Univ Medical Sci. 2021.
19. Wilking H, Thamm M, Stark K, et al. Prevalence, incidence estimations, and risk factors of Toxoplasma gondii infection in Germany: a representative, cross-sectional, serological study. Sci Rep. 2016; 6:22551.
20. Chiang T-Y, Kuo M-C, Chen C-H, et al. Risk factors for acute Toxoplasma gondii diseases in Taiwan: a population-based case-control study. PLoS One. 2014; 9(3).
21. Ali T, Sindhu Kaitha SM, Ftesi A, et al. Clinical use of anti-TNF therapy and increased risk of infections. Drug, Healthc Patient Saf. 2013; 5:79.
22. Gaffen SL. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep. 2009; 11(5):365.
23. Li Y-X, Xin H, Zhang X-Y, et al. Toxoplasma gondii infection in diabetes mellitus patients in China: Seroprevalence, risk factors, and case-control studies. Biomed Res Int. 2018; 2018.
24. Kaňková Š, Prochazkova L, Flegr J, et al. Effects of latent toxoplasmosis on autoimmune thyroid diseases in pregnancy. PloS One. 2014; 9(10).
25. Oruç S, Karakaya F, Demirbas H, Çeçen İ, Küsbeci ÖY, Yaman M, Miman Ö. Relationship of Toxoplasma Gondii Exposure with Multiple Sclerosis. Eur J Gen Med. 2016; 13(1).
26. Asgari Q, Motazedian MH, Khazanchin A, Mehrabani D, Naderi Shahabadi S. High Prevalence of Toxoplasma gondii Infection in Type I Diabetic Patients. J Parasitol Res. 2021; 2021.
|Issue||Vol 17 No 3 (2022)|
|Toxoplasmosis Toxoplasma gondii Rheumatoid arthritis Seroprevalence Patients|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|